Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study

NCT00553202 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00553202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00553202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
March 31, 2020
Enrollment
158 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia